GT Medical Technologies
Develops bioresorbable radiotherapy implants for surgical treatment of operable brain tumors
$100MSeries E
Role not disclosedVG
Viking Global Investors
Activity from announced rounds
Activity in this selectionJun 30, 2026 · Jun 1, 2026
- Rounds participated in
- 2
- Confirmed lead rounds
- — 2 roles undisclosed
- New companies
- 2 First participation on record · 0 follow-on
- Funding in participating rounds
- $199.5M 2 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
2 in this selectionCity Therapeutics
City Therapeutics develops RNA-interference therapeutics and an engineering platform across disease areas.
$99.5MSeries B
Role not disclosed